Peptide therapeutics would seem to occupy a sweet spot between small molecules and biologics. Small molecules, which represent the majority of clinical drugs, preferentially bind hydrophobic pockets or cavities, [...]
Circle Pharma Inc. said its first collaboration with Pfizer Inc. has led to the identification of a series of bioavailable macrocyclic peptides capable of acting as potent and cell-permeable modulators of CXCR7. [...]
Results from its collaborative work with Pfizer to develop a potent and orally bioavailable macrocycle modulator have been published [...]
David Spellmeyer, PhD, has been appointed as Circle Pharma's chief scientific officer [...]
Cyclic peptide natural products and their synthetic mimics have gained prominence as potential sources of next‐generation therapeutics and biological probes. The size and structural complexity of these compounds sets them apart from common synthetic drugs.
Read online book
The chemokine receptor CXCR7 is an attractive target for a variety of diseases. While several small molecule modulators of CXCR7 have been reported, peptidic macrocycles may provide advantages in terms of potency, selectivity, and reduced off-target activity.
Read online article
As interest in protein–protein interactions and other previously-undruggable targets increases, medicinal chemists are returning to natural products for design inspiration toward molecules that transcend the paradigm of small molecule drugs.
Read online article
An expansion of Series A financing has been completed, with new investors W.I. Harper Group, [...]
Macrocyclic peptides are considered large enough to inhibit “undruggable” targets, but the design of passively cell-permeable molecules in this space remains a challenge due to the poorly understood role of molecular size on passive membrane permeability.
Read online article
Series A financing round has been announced in which over $4.5M of shares have been issued [...]